Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
Takeda Pharmaceutical Co Ltd (NYSE:TAK) will acquire NDI-034858 from Nimbus Therapeutics, an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor for multiple…
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
The FDA has accepted Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) supplemental marketing application for the potential expanded use of TAKHZYRO (lanadelumab-flyo) for…
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Last week, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine, Qdenga, was approved in Indonesia for individuals six to 45 years of age.…
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating…
Takeda’s Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
Takeda Pharmaceutical Company Limited (NYSE:TAK) reported a fiscal 2021 core net profit of ¥663.7 billion, an increase of 1.3% from…
Takeda’s Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
Takeda Pharmaceutical Co Ltd (NYSE:TAK) shared new analyses of Livtencity (maribavir), including additional analyses from Phase 3 SOLSTICE trial data, which…
Takeda’s Angioedema Drug Shows Promising Action Against COVID-19 Infection
Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise…
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly acquired rare disease drug Ultomiris for a
Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact,